<DOC>
	<DOCNO>NCT03016312</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , open-label study evaluate safety efficacy atezolizumab combination enzalutamide compare enzalutamide alone participant mCRPC failure androgen synthesis inhibitor ( e.g. , abiraterone ) failure , ineligibility , refusal taxane regimen . Participants receive treatment investigator-assessed confirm radiographic disease progression per Prostate Cancer Working Group 3 ( PCWG3 ) criteria unacceptable toxicity .</brief_summary>
	<brief_title>IMbassador250 : A Study Atezolizumab ( Anti-PD-L1 Antibody ) Combination With Enzalutamide Participants With Metastatic Castration-Resistant Prostrate Cancer ( mCRPC ) After Failure Androgen Synthesis Inhibitor And Failure , Ineligibility For , Refusal Taxane Regimen</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Steroid Synthesis Inhibitors</mesh_term>
	<criteria>Eastern Cooperative Oncology Group performance status 0 1 Life expectancy great equal ( &gt; = 3 ) month Histologically confirm adenocarcinoma prostate Known castrateresistant disease serum testosterone le ( &lt; ) 50 nanogram per deciliter ( ng/dL ) prior surgical castration ongoing androgen deprivation duration study Progressive disease prior screen prostatespecific antigen ( PSA ) image per prostate cancer work group 3 ( PCWG3 ) criterion follow direct prior line therapy set medical surgical castration One prior regimen/line taxanecontaining regimen mCRPC refusal ineligibility taxanecontaining regimen One prior regimen/line androgen synthesis inhibitor mCRPC Availability representative tumor specimen site previously irradiate suitable determination program death ligand1 ( PDL1 ) status via central test Adequate hematologic end organ function Treatment approve anticancer therapy , include chemotherapy , immunotherapy , radiopharmaceutical hormonal therapy ( exception abiraterone ) , within 4 week prior initiation study treatment Treatment abiraterone within 2 week prior study treatment Structurally unstable bone lesion suggest impending fracture Known suspect brain metastasis active leptomeningeal disease Major surgical procedure diagnosis within 4 week prior initiation study treatment anticipation need major surgical procedure course study Active history autoimmune disease immune deficiency Prior allogeneic stem cell solid organ transplantation History idiopathic pulmonary fibrosis/inflammation Positive human immunodeficiency virus ( HIV ) test , active tuberculosis , active hepatitis B C virus ( HCV ) infection Prior treatment cluster differentiation ( CD ) 137 agonist immune checkpoint blockade therapy , include anti Cytotoxic T LymphocyteAssociated ( CTLA ) 4 , antiprogrammed death 1 ( PD1 ) , antiPDL1 therapeutic antibody Treatment systemic immunostimulatory agent within 4 week five halflives drug , whichever short , prior initiation study treatment Treatment systemic immunosuppressive medication within 2 week prior initiation study Prior treatment enzalutamide new hormonal androgen receptor inhibitor History seizure condition may predispose seizure include history unexplained loss consciousness transient ischemic attack within 12 month prior study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>